The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

MultiVersus will go offline on May 30, 2025. The free-to-play fighting game has failed to capture a strong player base, costing Warner Bros. upwards of $100 million by late 2024. MultiVersus will ...

PSMA-targeted Radioligand Therapy with 131I-LNTH-1095 Plus Enzalutamide versus Enzalutamide Alone in Chemotherapy-naïve Patients Whose Piflufolastat F 18-avid Metastatic Castration-resistant Prostate ...

On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with ...

That means you have a choice to make when buying a new copy of Windows, and deciding whether to splurge for Windows 11 Pro vs. Home can be tricky! To help you make the right choice I'll run ...

Data from the phase 3 CAPItello-281 trial showed that capivasertib plus abiraterone and androgen deprivation therapy significantly improved ... study of patients with metastatic castration-sensitive ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

AA has only recently been approved by the Italian regulatory authorities and become available in everyday clinical practice; ENZ will probably be approved in the near future. However, both drugs ...